Compile Data Set for Download or QSAR
Report error Found 267 Enz. Inhib. hit(s) with all data for entry = 11958
TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665067BDBM665067(US20240116892, Compound I-40)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665070BDBM665070(US20240116892, Compound I-42)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665080BDBM665080(US20240116892, Compound I-49-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665081BDBM665081(US20240116892, Compound I-49-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665075BDBM665075(US20240116892, Compound I-45-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665077BDBM665077(US20240116892, Compound I-46)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665056BDBM665056(US20240116892, Compound I-33-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665055BDBM665055(US20240116892, Compound I-33-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665058BDBM665058(US20240116892, Compound I-34-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665057BDBM665057(US20240116892, Compound I-34-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665052BDBM665052(US20240116892, Compound I-29-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665051BDBM665051(US20240116892, Compound I-29-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665054BDBM665054(US20240116892, Compound I-31)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665053BDBM665053(US20240116892, Compound I-30)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665064BDBM665064(US20240116892, Compound I-37-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665063BDBM665063(US20240116892, Compound I-37-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665066BDBM665066(US20240116892, Compound I-39)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665060BDBM665060(US20240116892, Compound I-35-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665059BDBM665059(US20240116892, Compound I-35-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665062BDBM665062(US20240116892, Compound I-36-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665061BDBM665061(US20240116892, Compound I-36-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665104BDBM665104(US20240116892, Compound I-64-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665103BDBM665103(US20240116892, Compound I-64-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665106BDBM665106(US20240116892, Compound I-66)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665105BDBM665105(US20240116892, Compound I-65)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665100BDBM665100(US20240116892, Compound I-62-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665099BDBM665099(US20240116892, Compound I-62-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665102BDBM665102(US20240116892, Compound I-63-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665101BDBM665101(US20240116892, Compound I-63-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665111BDBM665111(US20240116892, Compound I-70-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665114BDBM665114(US20240116892, Compound I-73)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665113BDBM665113(US20240116892, Compound I-72)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665108BDBM665108(US20240116892, Compound I-68)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665110BDBM665110(US20240116892, Compound I-70-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665109BDBM665109(US20240116892, Compound I-69)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665089BDBM665089(US20240116892, Compound I-55)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665097BDBM665097(US20240116892, Compound I-61-b | US20240116892, Co...)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665097BDBM665097(US20240116892, Compound I-61-b | US20240116892, Co...)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665092BDBM665092(US20240116892, Compound I-58-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665091BDBM665091(US20240116892, Compound I-57)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665094BDBM665094(US20240116892, Compound I-59)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665093BDBM665093(US20240116892, Compound I-58-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665135BDBM665135(US20240116892, Compound I-88-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665132BDBM665132(US20240116892, Compound I-87-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665131BDBM665131(US20240116892, Compound I-86)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665134BDBM665134(US20240116892, Compound I-88-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665133BDBM665133(US20240116892, Compound I-87-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665144BDBM665144(US20240116892, Compound I-95-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665143BDBM665143(US20240116892, Compound I-94)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandChemical structure of BindingDB Monomer ID 665145BDBM665145(US20240116892, Compound I-95-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

Displayed 1 to 50 (of 267 total ) | Next | Last >>
Jump to: